Jennison Associates’s Revance Therapeutics, Inc. RVNC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2024
Q1
Sell
-1,032,352
Closed -$9.07M 641
2023
Q4
$9.07M Buy
1,032,352
+34,736
+3% +$305K 0.01% 395
2023
Q3
$11.4M Sell
997,616
-841,651
-46% -$9.65M 0.01% 361
2023
Q2
$46.6M Buy
1,839,267
+205,962
+13% +$5.21M 0.04% 197
2023
Q1
$52.6M Sell
1,633,305
-392,720
-19% -$12.6M 0.05% 177
2022
Q4
$37.4M Buy
2,026,025
+953,790
+89% +$17.6M 0.04% 228
2022
Q3
$29M Sell
1,072,235
-683,468
-39% -$18.5M 0.03% 262
2022
Q2
$24.3M Sell
1,755,703
-685,583
-28% -$9.47M 0.02% 288
2022
Q1
$47.6M Buy
2,441,286
+237,722
+11% +$4.64M 0.04% 216
2021
Q4
$36M Buy
2,203,564
+118,038
+6% +$1.93M 0.02% 273
2021
Q3
$58.1M Buy
2,085,526
+142,946
+7% +$3.98M 0.04% 191
2021
Q2
$57.6M Sell
1,942,580
-158,403
-8% -$4.7M 0.04% 198
2021
Q1
$58.7M Sell
2,100,983
-100,525
-5% -$2.81M 0.04% 197
2020
Q4
$62.4M Sell
2,201,508
-84,534
-4% -$2.4M 0.04% 171
2020
Q3
$57.5M Buy
2,286,042
+159,501
+8% +$4.01M 0.05% 158
2020
Q2
$51.9M Buy
2,126,541
+424,017
+25% +$10.4M 0.05% 163
2020
Q1
$25.2M Buy
+1,702,524
New +$25.2M 0.03% 222
2018
Q4
Sell
-34,753
Closed -$864K 727
2018
Q3
$864K Sell
34,753
-1,097,207
-97% -$27.3M ﹤0.01% 561
2018
Q2
$31.1M Sell
1,131,960
-351,077
-24% -$9.64M 0.03% 336
2018
Q1
$45.7M Buy
1,483,037
+625,501
+73% +$19.3M 0.05% 266
2017
Q4
$30.7M Buy
857,536
+480,008
+127% +$17.2M 0.03% 330
2017
Q3
$10.4M Sell
377,528
-872
-0.2% -$24K 0.01% 477
2017
Q2
$9.99M Buy
+378,400
New +$9.99M 0.01% 476
2015
Q4
Sell
-78,156
Closed -$2.33M 728
2015
Q3
$2.33M Buy
78,156
+603
+0.8% +$17.9K ﹤0.01% 578
2015
Q2
$2.48M Sell
77,553
-31,814
-29% -$1.02M ﹤0.01% 593
2015
Q1
$2.27M Buy
109,367
+242
+0.2% +$5.02K ﹤0.01% 586
2014
Q4
$1.85M Sell
109,125
-190,069
-64% -$3.22M ﹤0.01% 601
2014
Q3
$5.78M Sell
299,194
-821,940
-73% -$15.9M 0.01% 495
2014
Q2
$38.1M Buy
1,121,134
+946,162
+541% +$32.2M 0.04% 361
2014
Q1
$5.51M Buy
+174,972
New +$5.51M 0.01% 504